ProQR Therapeutics (PRQR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board [Yahoo! Finance]
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]